BR9604881A - Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzida - Google Patents

Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzida

Info

Publication number
BR9604881A
BR9604881A BR9604881-6A BR9604881A BR9604881A BR 9604881 A BR9604881 A BR 9604881A BR 9604881 A BR9604881 A BR 9604881A BR 9604881 A BR9604881 A BR 9604881A
Authority
BR
Brazil
Prior art keywords
gastrointestinal toxicity
composition
reduced gastrointestinal
obtaining
neoplastic disease
Prior art date
Application number
BR9604881-6A
Other languages
English (en)
Inventor
William J Wechter
Original Assignee
Univ Loma Linda Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Loma Linda Med filed Critical Univ Loma Linda Med
Publication of BR9604881A publication Critical patent/BR9604881A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSIçãO, MéTODO DE OBTENçãO DE UM EFEITO QUIMIOPROTETOR COLORETAL COM TOXICIDADE GASTROINTESTINAL REDUZIDA E MéTODO DE TRATAMENTO DE DOENçA NEOPLáSTICA COM TOXICIDADE GASTROINTESTINAL REDUZIDA". A presente invenção se refere a composições e métodos utilizáveis na prevenção de câncer coloretal e outros canceres epiteliais gastrointestinais. A composição compreende uma R-NSAID enantiomericamente estável ou sal farmaceuticamente estável da mesma em uma quantidade eficaz para proporcionar um efeito quimioprotetor, substancialmente isenta do S-enantiómero da referida R-NSAID. O método compreender a administração da composição a um mamífero.
BR9604881-6A 1995-03-13 1996-03-13 Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzida BR9604881A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/402,797 US5955504A (en) 1995-03-13 1995-03-13 Colorectal chemoprotective composition and method of preventing colorectal cancer
PCT/US1996/003495 WO1996028148A2 (en) 1995-03-13 1996-03-13 Use of a r-nsaid in a protective composition for the treatment of colorectal cancer

Publications (1)

Publication Number Publication Date
BR9604881A true BR9604881A (pt) 1999-11-30

Family

ID=23593347

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9604881-6A BR9604881A (pt) 1995-03-13 1996-03-13 Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzida
BR9607212-1A BR9607212A (pt) 1995-03-13 1996-03-13 Uso de uma nsaid-r em uma composição de proteção para o tratamento de cancer de colo retal

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR9607212-1A BR9607212A (pt) 1995-03-13 1996-03-13 Uso de uma nsaid-r em uma composição de proteção para o tratamento de cancer de colo retal

Country Status (13)

Country Link
US (1) US5955504A (pt)
EP (1) EP0814796B1 (pt)
JP (1) JPH11502199A (pt)
CN (1) CN1183717A (pt)
AT (1) ATE296097T1 (pt)
AU (1) AU713569B2 (pt)
BR (2) BR9604881A (pt)
CA (1) CA2215329C (pt)
DE (1) DE69634776T2 (pt)
DK (1) DK0814796T3 (pt)
ES (1) ES2240992T3 (pt)
PT (1) PT814796E (pt)
WO (1) WO1996028148A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
AU3641597A (en) * 1996-06-21 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions comprising r-ibuprofen
EP1642575B1 (en) * 1997-03-10 2009-10-28 Loma Linda University Medical Center Use of r-carprofen for the prevention of alzheimer's disease
NZ509376A (en) 1998-07-09 2003-10-31 Francis A Nardella Indole or carbazole derivatives for the treatment of chronic lyphocytic leukemia
US6545034B1 (en) 1999-07-23 2003-04-08 The Regents Of The University Of California Use of etodolac for the treatment of chronic lymphocytic leukemia
US7151100B1 (en) 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7361680B2 (en) * 1999-07-23 2008-04-22 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7129262B2 (en) * 1999-07-23 2006-10-31 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
JP2005508838A (ja) 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
US20030232794A1 (en) * 2001-06-26 2003-12-18 Cottam Howard B. Use of STAT-6 inhibitors as therapeutic agents
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030027867A1 (en) * 2001-06-29 2003-02-06 Myriad Genetics, Incorporated Use of R-NSAID compounds for anti-HIV treatment
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
AU2003251587A1 (en) * 2002-08-22 2004-03-11 Cornell Research Foundation, Inc. Multifunctional cox-2 inhibitors
AU2003295336A1 (en) * 2002-09-19 2004-04-08 Dennis A. Carson Use of etodoclac to treat hyperplasia
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
JP2007507524A (ja) * 2003-10-02 2007-03-29 セフアロン・インコーポレーテツド インドール誘導体
JP5576592B2 (ja) * 2004-03-29 2014-08-20 キャンサー アドヴァンシズ インコーポレイテッド ガストリンホルモンに対するモノクローナル抗体
EP1794586B1 (en) 2004-09-22 2013-01-30 Cancer Advances, Inc., Monoclonal antibodies to progastrin
CN101933923A (zh) * 2004-11-05 2011-01-05 赛福伦公司 癌症治疗
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
US8357720B2 (en) * 2005-03-23 2013-01-22 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
US8258181B2 (en) * 2005-03-23 2012-09-04 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
MX2011002936A (es) * 2008-09-25 2011-04-11 Cephalon Inc Formulaciones liquidas de bendamustina.
CA2749101A1 (en) * 2009-01-15 2010-07-22 Cephalon, Inc. Novel forms of bendamustine free base
US9125899B1 (en) * 2010-06-17 2015-09-08 Stc.Unm Modulators of GTPases and their use
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
CA2871820C (en) 2012-05-10 2020-11-03 Painreform Ltd. Depot formulations of a hydrophobic active ingredient and methods for preparation thereof
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
CN115181105B (zh) * 2022-08-26 2024-05-28 长春亿诺科医药科技有限责任公司 R型酮咯酸的制备方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1091403A (en) * 1964-01-24 1967-11-15 Boots Pure Drug Co Ltd Therapeutically active phenylalkane derivatives
DE3824353A1 (de) * 1988-07-19 1990-01-25 Paz Arzneimittelentwicklung Verfahren zur trennung von gemischen enantiomerer arylpropionsaeuren
DE4028906A1 (de) * 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
FR2687915B1 (fr) * 1992-02-28 1995-05-05 Rhone Poulenc Rorer Sa Composition pharmaceutique utilisable comme analgesique contenant l'acide (benzoyl-3 phenyl)-2 propionique-(r).
US5331000A (en) * 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5382591A (en) * 1992-12-17 1995-01-17 Sepracor Inc. Antipyretic and analgesic methods using optically pure R-ketorolac
US5955504A (en) * 1995-03-13 1999-09-21 Loma Linda University Medical Center Colorectal chemoprotective composition and method of preventing colorectal cancer
US6160018A (en) * 1995-03-13 2000-12-12 Loma Linda University Medical Center Prophylactic composition and method for alzheimer's Disease
AU3641597A (en) * 1996-06-21 1998-01-07 Advanced Research And Technology Institute, Inc. Methods and compositions comprising r-ibuprofen
US7105560B1 (en) * 1999-07-23 2006-09-12 The Regents Of The University Of California Use of etodolac in the treatment of multiple myeloma

Also Published As

Publication number Publication date
EP0814796A2 (en) 1998-01-07
AU5422796A (en) 1996-10-02
DK0814796T3 (da) 2005-09-19
PT814796E (pt) 2005-08-31
US5955504A (en) 1999-09-21
CA2215329A1 (en) 1996-09-19
ATE296097T1 (de) 2005-06-15
BR9607212A (pt) 1999-11-30
AU713569B2 (en) 1999-12-02
WO1996028148A2 (en) 1996-09-19
CN1183717A (zh) 1998-06-03
DE69634776D1 (de) 2005-06-30
WO1996028148A3 (en) 1996-11-14
JPH11502199A (ja) 1999-02-23
CA2215329C (en) 2007-09-04
DE69634776T2 (de) 2006-05-11
EP0814796B1 (en) 2005-05-25
ES2240992T3 (es) 2005-10-16

Similar Documents

Publication Publication Date Title
BR9604881A (pt) Composição, método de obtenção de um efeito quimioprotetor coloretal com toxicidade gastrointestinal reduzida e métodode tratamento de doença neoplástica com toxicidade gastrointestinal reduzida
FI973163A (fi) Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)-desetyylioksibutyniiniä
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
ATE340581T1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
IS4972A (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
CA2339384A1 (en) Improved method for targeted topical treatment of disease
PT1173201E (pt) Metodo para o tratamento de fibrose utilizando um antagonista da subunidade alfa 4 de integrina
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
MY104521A (en) Treatment of depression.
MXPA01012936A (es) Composicion farmaceutica que contiene sibutramina y orlistat.
DE10299023I1 (de) Antineoplastisch wirkender und den Antineoplastischen effekt Verstaerkender Wirkstoff
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
DK0541726T3 (da) Vækstfaktorsammensætninger, fremstilling og anvendelse
TR200102262T2 (tr) Koroner müdahale ile ilgili kardiovasküler olayların önlenmesi veya azaltılması için yöntem.
RU94002713A (ru) Способ лечения детей с синдромом удлиненного интервала qт (романо-уорда)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]